Hoyt, SB; Finocchio, CJ; Croll, E; Tawa, GJ; Li, H; Ma, L; Li, K; Liu, L; Li, R; Zhang, X; Culver-Cochran, AE; Rosenbaum, JS; Starczynowski, DT; Thomas, CJ. Discovery of IRAK1/4/pan-FLT3 Kinase Inhibitors as Treatments for Acute Myeloid Leukemia. ACS Medicinal Chemistry Letters. 2024; 15:1843-1851.

LeBlanc, FR; Breese, EH; Burns, KC; Chang, EK; Jones, LQ M; Lee, L; Mizukawa, B; Norris, RE; O'Brien, MM; Phillips, CL; Perentesis, JP; Rubinstein, J; Pommert, L. Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients. British Journal of Haematology. 2024; 205:1055-1066.

Jones, LQ M; Starczynowski, DT. IKAROS and MENIN in synergy in AML. Nature Cancer. 2022; 3:528-529.

Jones, LM; Tarlock, K; Cooper, T. Targeted Therapy in Pediatric AML: An Evolving Landscape. Pediatric Drugs. 2021; 23:485-497.

Jones, LM; Regan, C; Wolf, K; Bryant, J; Rakowsky, A; Pe, M; Snyder, DA. Effect of osteopathic manipulative treatment on pulmonary function testing in children with asthma. Journal of Osteopathic Medicine. 2021; 121:589-596.

Jones, L; Melgar, K; Hoyt, S; Wunderlich, M; O’Brien, E; Perentesis, J; Thomas, C; Starczynowski, D. 81030 Utilizing a synergistic drug combination to target relapsed/refractory FLT3 mutant AML. Journal of Clinical and Translational Science. 2021; 5:100.

Jones, LM; O'Brien, MM; Breese, EH; Absalon, M; Burns, KC; Grimley, M; Mizukawa, B; Lee, LH; Perentesis, JP; Phillips, CL. Methylation profiling of hypomethylating agent response and treatment failure in pediatric and young adult MDS/AML. Journal of Clinical Oncology. 2020; 38:e22502.

Jones, LM; Melgar, K; Bolanos, L; Hueneman, K; Walker, MM; Jiang, J; Wilson, KM; Zhang, X; Shen, J; Jiang, F; O'Brien, E; Perentesis, JP; Starczynowski, DT; Thomas, CJ. Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. The Journal of Clinical Investigation. 2020; 130:2017-2023.